Izvorni znanstveni članak
The association between the recurrence of solitary nonmuscle invasive bladder cancer and tumor infiltrating lymphocytes
Kristian Krpina
; Department of Urology, Clinical Hospital Center Rijeka, Rijeka, Croatia
Emina Babarović
; Department of Pathology, School of Medicine, University of Rijeka, Rijeka, Croatia
Gordana Đorđević
; Department of Pathology, School of Medicine, University of Rijeka, Rijeka, Croatia
Željko Fučkar
; Department of Urology, Clinical Hospital Center Rijeka, Rijeka, Croatia
Nives Jonjić
; Department of Pathology, School of Medicine, University of Rijeka, Rijeka, Croatia
Sažetak
Aim To evaluate whether tumor infiltrating lymphocytes
(TIL) in biopsy specimens are associated with the clinical
outcome of non-muscle invasive bladder cancer.
Methods We retrieved tumor specimens from 115 patients
with solitary papillary non-muscle invasive bladder
cancer treated between 1996 and 2006 and constructed
tissue microarrays. Patients were divided in two groups:
those with recurrent disease (N = 69) and those without recurrent
disease (N = 46) during the follow up of minimum
5 years. All patients were treated with initial transurethral
resection and none received adjuvant therapy. Immunhistochemical
staining was performed with anti-CD3, CD4,
CD8, and Granzyme B (GrB). The CD4+:CD8+ and GrB+:CD8
ratios were determined.
Results Tumor infiltrating lymphocytes were predominantly
observed within cancer stroma, and only rare individual
cells were observed intraepithelially. The group
without recurrent disease had lower levels of CD3+ and
CD8+ lymphocytes than the group with recurrent disease
(P = 0.0001, P = 0.0002, respectively). The CD4+:GrB+ and
GrB+:CD8+ ratios were significantly higher in patients without
recurrent disease (P = 0.0002, P = 0.039, respectively).
Conclusion This study revealed a possible connection between
TIL number and bladder cancer recurrence. TIL subset
ratio showed different patterns in recurrent and nonrecurrent
tumors, which is why it could become a useful
a prognostic clinical index if our findings are confirmed in
randomized trials.
Ključne riječi
Hrčak ID:
95884
URI
Datum izdavanja:
15.12.2012.
Posjeta: 1.389 *